Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials is a research paper published in Journal of the National Comprehensive Cancer Network (2022). On theSindex it has a DataRank of 0.461. It has been cited 8 times, with 8 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0.131
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 8 citers.
NCATS NIH HHS
Grant: UL1 TR001105
NCI NIH HHS
Grant: R01 CA229834
NCI NIH HHS
Grant: K24 CA201543
NCI NIH HHS
Grant: UG1 CA233302
National Institutes of Health
Grant: 4UL1TR001105-04
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)
National Institutes of Health
Grant: 5K24CA201543-04
Development of New Cancer Treatments and Investigators
National Institutes of Health
Grant: 5R01CA229834-03
Revisiting Prior Cancer as an Exclusion Criterion for Cancer Clinical Trials
FWCI
1.16
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals